Supernus Pharmaceuticals: Key Risks Investors Face and a Safer Stock Alternative to Consider | MarketWire
Supernus Pharmaceuticals outperformed the S&P 500 in the past 6 months, but risks loom ahead. Learn more about implications and an alternative to watch.